GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Ending Cash Position

ANRO (Alto Neuroscience) Ending Cash Position : $168.73 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Ending Cash Position?

Alto Neuroscience's Ending Cash Position for the quarter that ended in Dec. 2024 was $168.73 Mil.

Alto Neuroscience's quarterly Ending Cash Position declined from Jun. 2024 ($193.62 Mil) to Sep. 2024 ($182.20 Mil) and declined from Sep. 2024 ($182.20 Mil) to Dec. 2024 ($168.73 Mil).

Alto Neuroscience's annual Ending Cash Position increased from Dec. 2022 ($48.34 Mil) to Dec. 2023 ($82.55 Mil) and increased from Dec. 2023 ($82.55 Mil) to Dec. 2024 ($168.73 Mil).


Alto Neuroscience Ending Cash Position Historical Data

The historical data trend for Alto Neuroscience's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Ending Cash Position Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Ending Cash Position
25.71 48.34 82.55 168.73

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.55 205.90 193.62 182.20 168.73

Alto Neuroscience Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Alto Neuroscience's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=82.548+86.181
=168.73

Alto Neuroscience's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=182.201+-13.472
=168.73


Alto Neuroscience Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience Business Description

Traded in Other Exchanges
N/A
Address
650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.